Direct Answer
Allergy and immunology billing is centered on two high-volume service categories: (1) allergy testing — percutaneous scratch tests, intradermal tests, and patch tests — where the number of tests performed drives code selection; and (2) allergen immunotherapy — subcutaneous injection series where the practice bills separately for the preparation of the antigen (mixing the extract) and the administration of the injection. These two components of immunotherapy (preparation and injection) are billed separately and have different rules depending on whether the practice bills for both or only one. Additionally, the specialty has growing procedure revenue from biologic injections for asthma (omalizumab, dupilumab, mepolizumab) and IVIG administration for primary immunodeficiency disorders.
Table of Contents
Allergy Testing CPT Codes
Allergy testing CPT codes are billed per test — the number of allergens tested drives the claim. Accurate test counts are essential for correct code selection: Percutaneous (scratch/prick) tests: 95004 — Percutaneous tests (scratch, puncture, prick), immediate type reaction, specify number of tests; billed in units = number of individual allergens tested by percutaneous method; example: 95004 × 60 for 60 percutaneous tests; Intradermal tests: 95024 — Intradermal tests, with allergenic extracts, immediate type reaction, specify number of tests; 95028 — Intradermal tests, with allergenic extracts, delayed type reaction, including reading; 95027 — Intradermal tests, sequential and incremental, with allergenic extracts for airways hyper-reactivity, immediate type reaction; units = number of intradermal tests; Patch tests (delayed hypersensitivity): 95044 — Patch or application test(s), specify number of tests; used for contact dermatitis evaluation; Photo patch tests: 95052 — Photo patch test(s), specify number of tests; Additional allergen-specific testing: 95056 — Photo tests; 95060 — Ophthalmic mucous membrane tests; 95065 — Nasal mucous membrane tests; 95070 — Bronchial challenge test; 95071 — Bronchial provocation challenge with serial PFTs; Interpretation and report: 95004 and other allergy testing codes include the physician's interpretation as part of the test — a separate interpretation charge is not separately billable for allergy skin tests; allergen-specific IgE (RAST) tests: when blood tests rather than skin tests are used for allergen-specific IgE, bill laboratory codes (86003 per allergen — allergen specific IgE; quantitative); 86003 is billed per allergen tested; NCCI edits and bundling: you cannot bill both 95004 and 95024 for the same allergen on the same visit (skin prick AND intradermal for same allergen); however, intradermal testing may follow a negative prick test for specific allergens as part of a tiered protocol — document the protocol justification.
Allergen Immunotherapy Billing
Allergen immunotherapy (allergy shots) billing has two distinct components — preparation and injection administration — that are billed separately and can be billed by different providers: Preparation (antigen/extract mixing): 95165 — Professional services for allergen immunotherapy, not including provision of allergenic extracts; stinging insect venom; single or multiple antigens; specify number of doses; 95165 is the preparation fee — it covers the physician's professional service in prescribing and supervising the preparation of the extract vials; it is NOT the injection administration fee; billing 95165: billed per dose prepared (one dose = one injection vial fill); if 3 vials of 10 doses each are prepared, bill 95165 × 30; Injection administration (single antigen): 95115 — Professional services for allergen immunotherapy in prescribing physician's office or institution; single injection; 95117 — Two or more injections; Stinging insect venom immunotherapy: 95130 — Single stinging insect venom; 95131 — Two stinging insect venoms; 95132 — Three stinging insect venoms; 95133 — Four; 95134 — Five; Preparation AND injection same provider: when the same provider both prepares the extract and administers the injection on the same day: bill 95165 for the preparation (units = doses prepared) plus 95115 or 95117 for the injection administration; Injection administration only (home program/outside provider): when the patient brings their own extract to a different provider (e.g., primary care office administers the shots the allergist prepared): the administering provider bills 95115 or 95117 only — they did NOT prepare the extract; the allergist bills 95165 for the preparation; Rush immunotherapy: 95180 — Rapid desensitization procedure, one hour; used for rush immunotherapy protocols; Sublingual immunotherapy (SLIT): 95833 and other codes depending on the formulation; SLIT is less uniformly covered than SCIT — verify each payer's coverage policy; some payers cover FDA-approved SLIT tablets (Grastek, Odactra, Ragwitek) but not compounded SLIT drops.
IVIG Billing for Immunodeficiency
Intravenous immunoglobulin (IVIG) administration for primary immunodeficiency disorders is a significant revenue source for immunology practices: Coverage criteria for IVIG: Medicare and most commercial payers cover IVIG for: primary immunodeficiency disorders (common variable immunodeficiency, X-linked agammaglobulinemia, combined immunodeficiency); IgG level documentation: IgG trough levels below 400-500 mg/dL (or documented symptomatic immunodeficiency) are typically required for initial coverage; ongoing coverage requires documented clinical response; Administration codes: 96365 — IV infusion, initial, up to 1 hour; 96366 — Each additional hour (add-on); IVIG infusions are long (typically 3-6 hours for standard doses); document total infusion time; Drug HCPCS codes for IVIG: J1459 — Injection, immune globulin (Privigen), IV, non-lyophilized (e.g., liquid), 500 mg; J1554 — Injection, immune globulin (Xembify), subcutaneous, 100 mg; J1561 — Injection, immune globulin (Gamunex-C/Gammaked), non-lyophilized, 500 mg; J1566 — Injection, immune globulin, IV, lyophilized (e.g., powder), 500 mg; J1569 — Injection, immune globulin (Gammagard liquid), non-lyophilized, 500 mg; J1572 — Injection, immune globulin (Flebogamma/Flebogamma DIF), IV, non-lyophilized; J1575 — Injection, immune globulin/hyaluronidase (HyQvia), subcutaneous infusion, 100 mg immunoglobulin; Subcutaneous immunoglobulin (SCIG): increasing number of immunodeficiency patients transition from IVIG to home SCIG therapy; SCIG may be administered in the office or at home via a home infusion company; for office-based SCIG: administration code 96369 (subcutaneous infusion) + drug HCPCS code; NDC requirement: document the specific product NDC number; dosing and units: IVIG is dosed in grams per kilogram body weight; bill drug HCPCS codes in the units specified by the code description (per 500 mg for most IVIG codes); verify units match what was administered.
Biologic Injections for Asthma and Allergy
Several FDA-approved biologic agents target allergic conditions and are increasingly administered in the allergy office: Omalizumab (Xolair) for allergic asthma and chronic urticaria: J2357 — Injection, omalizumab, 5 mg; administered subcutaneously; dose is weight-based and IgE-based; administered every 2-4 weeks; prior authorization required; step therapy requirements (failure of high-dose ICS, LABA) typically required; Dupilumab (Dupixent) for eosinophilic asthma and atopic dermatitis: J0173 — Injection, dupilumab, 1 mg; prior authorization required; step therapy with ICS/LABA and biologic alternatives documented; Mepolizumab (Nucala) for eosinophilic asthma: J2182 — Injection, mepolizumab, 1 mg; eosinophil count documentation required (typically ≥150 cells/μL at initiation); administered monthly; Benralizumab (Fasenra) for eosinophilic asthma: J0517 — Injection, benralizumab, 1 mg; Tezepelumab (Tezspire) for severe uncontrolled asthma: J3246 — Injection, tezepelumab-ekko, 1 mg; Administration code for subcutaneous biologics: 96372 — Therapeutic, prophylactic, or diagnostic injection, SC or IM; billed in addition to the drug HCPCS code; 96372 is billed once per injection session regardless of dose or volume; Observation period billing: omalizumab requires a minimum 20-minute post-injection observation period for anaphylaxis monitoring; 30-60 minute observation is required after the first 3 injections; the observation period is included in the office visit — not separately billed; Prior authorization for asthma biologics: most require PA with documentation of: severe or poorly controlled asthma despite optimized inhaled therapy; eosinophil count or IgE level (depending on the agent); failure of previous asthma controller medications; specific ICD-10 code that matches the FDA-approved indication.
Allergy Practice Revenue Cycle Management
Allergy practices have distinctive revenue cycle characteristics driven by high ancillary service volume and the allergy shot program: Allergy testing volume and documentation: large allergy practices may perform 50-100 skin tests per day; the claim must accurately reflect the number of tests performed; the test documentation (allergen tested, method, reaction size in mm) must be in the chart for each unit billed; Immunotherapy tracking: maintain a tracking system for each patient's immunotherapy program including: vials prepared; doses administered; the provider who administered; injection reactions documented; the billing for 95165 (preparation) must match the documented vials and doses prepared; E&M with allergy testing: an E&M on the same day as allergy testing: Modifier 25 is required on the E&M to indicate it is separately identifiable from the testing; when a new patient evaluation is conducted at the same visit where testing is performed, the comprehensive new patient E&M (99205) plus the testing codes are appropriate; Insurance verification for allergy testing and immunotherapy: some plans cover allergy testing but have per-visit or per-year limits on the number of tests; verify the specific benefit limits; some plans require that allergy testing be performed by a board-certified allergist to be covered; Sublingual immunotherapy coverage: SLIT drops (compounded) are not FDA-approved and are not covered by Medicare or many commercial payers; SLIT tablets (FDA-approved) are covered by Medicare under Part D (pharmacy benefit) — if administered in the office, they must be billed to Part D through a pharmacy; advise patients about the benefit split (SLIT tablets through pharmacy vs. SCIT through medical benefit); Biologic care management: patients on monthly biologic injections have predictable recurring visits with high drug costs; managing the prior authorization renewal cycle (typically annual) for each biologic patient is an important allergy practice administrative function.
FAQ
How is allergen immunotherapy billing split between the allergist who prepares the extract and the provider who administers the injections?
This is one of the most distinctive billing scenarios in allergy practice — the preparation and administration of allergen immunotherapy can be split between two different providers, each billing for their respective component. Understanding who bills what prevents both underbilling and duplicate billing. The two components of SCIT billing: Preparation component (95165): 95165 — Professional services for allergen immunotherapy, including provision of allergenic extracts, single or multiple antigens, specify number of doses; who bills it: the physician/practice that prepares the patient's customized extract vials; what it covers: the physician's professional service in: evaluating the patient's test results; prescribing the allergen mix; supervising the preparation of the extract vials; how it is billed: per dose prepared; one "dose" equals one injectable dose from the vial; if 3 vials with 10 doses each are prepared at one session, bill 95165 × 30; 95165 includes the cost of the allergenic extract itself — the cost of the antigens is embedded in the payment; Administration component (95115/95117): who bills it: the provider who actually gives the injection; this may be the allergist, a primary care provider, or any provider set up to administer the shots; what it covers: the professional service of administering the injection, monitoring the patient for reactions; 95115 — single injection; 95117 — two or more injections; The home program model: an allergist prepares a patient's extract vials (bills 95165); the vials are sent home with the patient or to the patient's primary care doctor; the primary care provider administers the injections (bills 95115/95117); in this model: the allergist bills 95165 whenever new vials are prepared (e.g., every few months); the PCP bills 95115/95117 at each injection visit; neither provider bills the other's component; both providers must have separate agreements with the payer; In-office model: when the allergist both prepares AND administers the injections: bill 95165 for the preparation (when vials are prepared) AND 95115/95117 for the injection administration at each injection visit; 95165 is not billed every injection visit — only when extract vials are prepared (typically every several months or when the patient advances to a new vial set); documentation: the extract preparation must be documented with the date, antigens included, concentrations, and number of doses prepared; the injection must be documented with the allergen administered, site, dose, observation period, and any local or systemic reactions.
What are the step therapy and prior authorization requirements for asthma biologics, and how should practices document failed prior therapy?
Asthma biologics (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) are among the most prior-authorization-intensive medications in allergy practice. PA approval rates improve dramatically with thorough step therapy documentation. Standard step therapy requirements by payer type: Most commercial payers require documentation of: confirmed asthma diagnosis (spirometry with bronchodilator reversibility is preferred over symptom-based diagnosis alone); severe or poorly controlled asthma despite high-dose ICS/LABA: document the specific ICS/LABA combination used, dose (must be high-dose ICS — e.g., fluticasone ≥500 mcg/day), duration of trial (typically ≥3-6 months at therapeutic dose), and continued poor control despite therapy; specific biomarker criteria: omalizumab requires perennial allergen sensitization (skin test or RAST positive) and total serum IgE 30-700 IU/mL; mepolizumab, benralizumab require blood eosinophil count ≥150 cells/μL at initiation (≥300 cells/μL for some payers); dupilumab — eosinophil count ≥300 cells/μL or oral corticosteroid dependence; tezepelumab — no biomarker threshold required (suitable for non-eosinophilic asthma); Documenting failed prior therapy: the PA letter and medical record must show: asthma action plan in place and given to patient; albuterol use >2 days/week (confirming poor control); nighttime awakening due to asthma (confirms poor control); any asthma exacerbations requiring oral steroids or ED/hospital visits in the past 12 months (most valuable documentation for medical necessity); specific prior medications tried (including generic names, brand names, doses, and dates); reason for failure of prior medications (poor control despite adherence, intolerable side effects, or contraindication); Renewal PA: continued authorization requires: documentation of clinical response (at least partial response — reduction in exacerbation frequency or oral steroid use); adherence documentation; ongoing poor control on conventional therapy alone; practices should schedule a dedicated "biologic renewal" documentation visit 1-2 months before PA expiration to capture current disease status, response to biologic therapy, and all supporting metrics needed for the renewal submission.
Allergy and Immunology Billing Expertise for Testing, Immunotherapy, and Biologics
Valiant Lifecare's allergy billing specialists handle allergy testing unit billing, immunotherapy preparation and injection billing split between providers, IVIG administration and drug HCPCS coding, biologic injection prior authorization and step therapy documentation, and allergy practice revenue cycle management — capturing every component of the allergy specialty's complex billing structure.
Optimize Your Allergy and Immunology Billing